Liquidia Technologies has formed a new pharmaceutical company, Lq3 Pharmaceuticals, dedicated to advancing novel therapies for oral health conditions.
Leveraging the firm's Particle Replication in Nonwetting Templates (PRINT) technology, Lq3 will initially focus on research and preclinical development of a currently undisclosed oral health product candidate. PRINT is a micro- and nanoparticle development and manufacturing platform designed to control particle size, shape, and chemistry, according to Liquidia.
Kyle Chenet, formerly vice president of corporate development for Liquidia and Envisia, has been named Lq3's chief executive officer.
"The oral health market is poised for significant growth, driven in part by an increased understanding of the linkage between oral inflammation and infection and systemic diseases such as diabetes, obesity, and other inflammatory diseases," Chenet said in a statement. "I am honored to have the opportunity to leverage our unparalleled technology to develop novel medicines that can have a significant impact on patients' lives."
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
